Adjuvant octreotide for neuroendocrine cancers – pro
The incidence rate of pancreatic neuroendocrine tumors (panNET) is increasing continuously. Curative resection was the primary treatment choice, as was done in this case. adjuvant therapy, it was of great importance to identify patients with high risks of recurrence after curative surgery and previous studies found that high ki-67 index, large tumor size, lymphatic metastasis and perineural/vascular invasion, and so on, were correlated with early recurrence of panNET. Since PRRT and chemotherapy were more cytotoxic, these two kinds of therapies might be worth trying as adjuvant therapies in patients with high risks of recurrence after curative resection of panNET. A recent article by L. Chen et al reviewed adjucant octreotide and concluded that there were no studies directly investigated neo-adjuvant/conversion and adjuvant therapy for panNET. Neither is it known how long to treat after resection. Therefore, more prospective studies were still warranted.
NCCN does not recommend adjuvant therapy for panNET cancers.
L. Chen et al, Perspective of neo-adjuvant/conversion and adjuvant therapy for pancreatic neuroendocrine tumors. Journal of Pancreatology: September 2019 – Volume 2 – Issue 3 – p 91
NCCN PanNet-6 2020